Biotech turns Pharma: Medivir's continuing evolution.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biotech turns Pharma: Medivir's continuing evolution.
Released on: August 08, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Medivir’s Business Development Director, Morten Faester talks to Fintan Walton at AngloNordic Life Science Conference, 2014 in London.
  • Summary
  • Transcript
  • Participants
  • Company
Medivir’s Business Development Director, Morten Faester talks to Fintan Walton at AngloNordic Life Science Conference, 2014 in London. Astra’s antiviral spinout has licensed a cold sore product to GlaxoSmithKline and co-developed a hepatitis C treatment with Janssen all while retaining their Nordic rights. Morten tells Fintan how the emerging speciality pharma of Northern Europe is looking towards new therapeutic areas such as oncology.
Medivir’s Business Development Director, Morten Faester talks to Fintan Walton at AngloNordic Life Science Conference, 2014 in London. Astra’s antiviral spinout has licensed a cold sore product to GlaxoSmithKline and co-developed a hepatitis C treatment with Janssen all while retaining their Nordic rights. Morten tells Fintan how the emerging speciality pharma of Northern Europe is looking towards new therapeutic areas such as oncology.
Morten Faester
Medivir
Medivir
On Medivir we work in all phases of drug discovery. Some projects we run in-house and some projects we run in conjunction with various partners. Our research focuses on infectious diseases and we have a leading position in hepatitis C.